Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vivani Medical, Inc.

NASDAQ: VANI · Industrial Applications and Services · 8 alerts · CIK 1266806

Share price
$1.02Close, Nov 16
Market cap
$92M
Shares outstanding
90.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vivani Medical, Inc. filings on SEC EDGAR ↗

4:37 PM ET 8-K
Capital Raise

Vivani Medical Capital Raise of $5.1M

Vivani Medical entered into a share purchase agreement for a $5.1 million private placement of common stock with board members Gregg Williams and Aaron Mendelsohn. The shares were priced at $1.01 per share, representing an at-the-market transaction based on the prior trading day's close. Proceeds will be used to fund the clinical development of NPM-139, the company's semaglutide implant for weight maintenance.

Value
$5.1M
Counterparty
Gregg Williams and Aaron Mendelsohn
8:01 AM ET Form 4
Insider Buying

Vivani Medical Insider Gregg Williams Buys $47.8K of Stock

Gregg Williams bought 48,100 shares of Vivani Medical, Inc. at $0.993 a share, worth $47.8K in total on Nov 13, 2026. Shares held after the trade: 36,960,836 (+0.1%).

Value
$47.8K
Shares
48,100
Price
$0.9930
Holding change
+0.1%
Trade date
Nov 13, 2026
9:32 PM ET Form 4
Insider Buying

Vivani Medical Chief Business Officer Donald Dwyer Buys $15.5K of Stock

Donald Dwyer, Chief Business Officer, bought 15,000 shares of Vivani Medical, Inc. at $1.03 a share, worth $15.5K in total on Nov 12, 2026. Shares held after the trade: 75,000 (+25.0%).

Value
$15.5K
Shares
15,000
Price
$1.03
Role
Chief Business Officer
Holding change
+25.0%
Trade date
Nov 12, 2026
8:30 AM ET 8-K
Clinical Trial Data

Vivani Medical Clinical Trial Data

Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial evaluating NPM-139, a miniature semaglutide implant for chronic weight management. The trial demonstrated that NPM-139 was well-tolerated with no treatment-related adverse events and achieved weight loss of 0.79% over four weeks, comparable to the 0.82% observed in the Wegovy control group.

Term
4 weeks

“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”

Adam Mendelsohn, PhD, CEO

“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”

Adam Mendelsohn, PhD, CEO
8:01 AM ET 10-Q
Financial Results

Vivani Medical Q3 2026 Results: Net Loss of $7.25M, Loss Widens

Vivani Medical, Inc. is a clinical-stage company with a cash balance of $14.6 million as of September 30, 2026, down from $16.2 million at year-end 2025. The company remains pre-revenue, focusing on the development of product candidates like NPM-139 and NPM-133, and reported a total liability of $22.1 million primarily driven by lease obligations.

Key figure
Net loss $7.25M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.